NCT06367114View on ClinicalTrials.gov

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

ssCART-19

"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

Trial Locations (2)

201210

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai

Unknown

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Peking University People's Hospital

OTHER

lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY